Former Merck Unit Works on First Vaccine for Hepatitis C

Okairos AG, a biotechnology business that Merck & Co. sold to venture capital funds in 2007, is seeking to produce the first preventive vaccine for hepatitis C, challenging makers of treatments for the disease.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.